United States · FDA National Drug Code directory
XELJANZ XR
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 63539-502_e8ed9fec-0cc3-403c-a731-72a6f8969afa
- Product NDC
- 63539-502
- Form
- TABLET, EXTENDED RELEASE
- Composition / generic term
- tofacitinib
- Labeler
- U.S. Pharmaceuticals
- Marketing category
- NDA
- Marketing start / end (source format)
- 20200121
- Source listing expiry
- 20271231
Source-listed ingredients
- TOFACITINIB CITRATE — 22 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (63539-502-30) · 63539-502-30
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →